Dialysis industry news

Stories from the dialysis comunity across the globe.



MIssissippi CON Report - June 1, 2012 - JD Supra (press release) PDF Print

Bradley Arant Boult Cummings LLP's Mississippi CON Report dated June 1, 2012, and including activities by and filings with the Mississippi State Department of Health's Office of Health Planning and Policy is provided for the firm’s health care clients and other interested parties. The firm’s Certificate of Need practice involves a cross-disciplinary team approach, involving transactional, regulatory, and government relations attorneys. Firm attorneys monitor legislative, regulatory, judicial, and administrative developments related to health planning; routinely advise clients on how these developments affect clients’ health care businesses; and guide clients through the requirements and regulatory hurdles for client acquisitions, development, and expansions.

In This Report:

- I. May 31, 2012 - Mississippi Certificate Of Need Meeting

- II. Certificate Of Need Program Report – Filings/Reports Since April 2012 CON Meeting

Please see full report below for more information.

...

 
Research and Markets: Renal Denervation Market - Current Situation Future ... - Business Wire (press release) PDF Print

DUBLIN--(BUSINESS WIRE)--Research and Markets (http://www.researchandmarkets.com/research/4fkjfc/renal_denervation) has announced the addition of the "Renal Denervation Market - Current Situation & Future Outlook" report to their offering.

“Renal Denervation Market - Current Situation & Future Outlook”

Renal artery denervation, a new device-based therapeutic paradigm for managing treatment resistant hypertension, has come of age and is attracting an unprecedented gold rush from serial medical device entrepreneurs.

Medtronic's acquisition of Ardian for $800 million plus $500 million more in milestone payments in January 2011 signaled the dawning of a new era of catheter-based renal denervation systems.

Results of the Symplicity HTN-1 and Symplicity HTN-2 trials have generated considerable interest among physicians, patients, medical device entrepreneurs, and the investment community.

The market, although still in the inception phase, has already attracted heavy hitters with Covidien paying $230 Million for Maya Medical' OneShot renal denervation system, St. Jude launching its EnligHTN renal denervation system in Europe in May 2012 and Boston Scientific diverting its R&D resources for a first-in-man with a new device before the end of 2012.

Renal denervation is a catheter-based therapy that uses either radiofrequency or ultrasound energy to disrupt the renal arteries sympathetic nerves whose hyperactivity may lead to treatment-resistant hypertension.

Renal denervation systems are perhaps the hottest medical device innovation space this year as they offer a complementary approach to the management of resistant hypertension that was not available before.

Renal Denervation Market report attempts to answer some important questions regarding the fast evolving market by examining Leading companies technologies, product offerings, market shares. The report offers a credible forecast to 2016.

Companies Mentioned

- Ardian

- Boston Scientific

- CardioSonic

- Covidien

- Kona Medical

- Maya Medical

- Mercator MedSystems

- Medtronic

- ReCor Medical

- St. Jude Medical

- Vessix Vascular

For more information visit http://www.researchandmarkets.com/research/4fkjfc/renal_denervation

...

 
Mayo Clinic children's specialties get top ranking - Post-Bulletin PDF Print
By Post-Bulletin staff


Mayo Clinic has ranked among the best Midwest children's hospitals in the 2012-2013 U.S. New & World Reports Best Children's Hospitals rankings.

According to the clinic, Mayo was the only Minnesota hospital to rank in all 10 pediatric specialties, including cancer, cardiology and heart surgery, diabetes and endocrinology, gastroenterology, neonatology, nephrology, neurology and neurosurgery, orthopedics, pulmonology and urology.

Dr. Ann Reed, chair of the Mayo Clinic Children's Center, said employees work diligently "to make each patient's experience the best it can be."

image

...

 
Positive results from Amgen Sensipar/Mimpara Phase 3 trial for HPT, CKD - News-Medical.net PDF Print
7e749cb5-1e79-4293-8d80-51b3f9cde1c4|0|.0

Posted in: Drug Trial News | Medical Condition News

Tags: , , , , , , , , , , , , , , , , , , , , , , , , ,

...

 
Amgen drug Sensipar fails to meet trial goal - Reuters UK PDF Print

Fri Jun 8, 2012 3:03pm BST

(Reuters) - Amgen Inc said on Friday a late-stage trial of its drug Sensipar failed to reduce the risk of death and cardiovascular problems in patients with a complication of kidney disease.

The goal of the study was to show a reduction in the risk of death, heart attack, unstable angina or heart failure in patients with chronic kidney disease who were receiving dialysis.

Although patients taking Sensipar experienced fewer events, the results were not statistically significant and the trial did not meet its goal, Amgen said in a statement.

Sensipar is approved to treat secondary hyperparathyroidism, a condition in which the body produces too much parathyroid hormone, a natural substance needed to control the amount of calcium in the blood. It can be a consequence of kidney failure.

Sensipar has been shown to lower calcium levels in the blood of patients who are on long-term dialysis for kidney disease. Amgen hoped to show it reduced death and heart risks.

Amgen's shares fell 22 cents, or 0.3 percent, to $68.88 in early trading on Nasdaq.

(Reporting By Toni Clarke; editing by M.D. Golan)

...

 
<< Start < Prev 581 582 583 584 585 586 587 588 589 590 Next > End >>

Page 583 of 4210
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.